Drug
Mogamulizumab
Mogamulizumab: highest development phase Post-Market, developed by Kyowa Kirin, Seagen. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Kyowa Kirin, Seagen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Mogamulizumab NCT06285370 | Post-Market | Cutaneous T-Cell Lymphoma |
| Mogamulizumab NCT05414500 | Phase 1 | Cutaneous T Cell Lymphoma |
Latest
No recent events.
Follow Mogamulizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.